| Budget Amount *help |
¥3,490,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥390,000)
Fiscal Year 2007: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2006: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Research Abstract |
1. Basic Research
To test a hypothesis that risk factors for stroke associated with atrial fibrillation (AF) could induce atrial endocardial dysfunction for themselves, we determined the expression level of tissue factor pathway inhibitor, thrombomodulin, eNOS, and PAI-1 in aged rats, SHR, and diabetic rats. Aging, hypertension, diabetes differentially down-regulated TFPI, TM, and eNOS in the atrial endocardium, suggesting that risk factors contribute to thrombus formation via atrial endocardial dysfunction. We also found out that the renin-angiotensin system plays a significant role in the atrial endocardial dysfunction by AF, using a specific AT1 blocker.
2. Clinical Research
Using our hospital-based cohort of Shinken Database 2004-5, we determined the effects of RAS inhibitors and statins on the incidence of stroke in AF patients. Among the total 4255 patients enrolled into the database, 657 patients had AF at the initial visit. Stroke was observed in 1.1% of patients with RAS inhibitors and in 0.9% of those without, respectively. Also, there were no significant differences between patients with and without statins. Further studies will be required to determine the utility of endocardium-targeted strategy.
|
